Literature DB >> 22538151

Analysis of the accuracy and precision of the Axis-Shield Afinion hemoglobin A1c measurement device.

Randie R Little1.   

Abstract

Point-of-care (POC) hemoglobin A1c measurement is now used by many physicians to make more timely decisions on therapy changes. A few studies have highlighted the drawbacks of some POC methods, e.g., poor precision and lot-to-lot variability. Evaluating performance in the clinical setting is difficult because there is minimal proficiency testing data on POC methods. In this issue of Journal of Diabetes Science and Technology, Wood and colleagues describe their experience with the Afinion method in a pediatric clinic network, comparing these results to another POC method as well as to a laboratory high-performance liquid chromatography method. Although they conclude that the Afinion exhibits adequate performance, they do not evaluate lot-to-lot variability. As with laboratory methods, potential assay interferences must also be considered.
© 2012 Diabetes Technology Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22538151      PMCID: PMC3380783          DOI: 10.1177/193229681200600225

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  8 in total

1.  Standards of medical care in diabetes--2006.

Authors: 
Journal:  Diabetes Care       Date:  2006-01       Impact factor: 19.112

2.  Effect of point-of-care on maintenance of glycemic control as measured by A1C.

Authors:  John R Petersen; Jane B Finley; Anthony O Okorodudu; Amin A Mohammad; James J Grady; Mandeep Bajaj
Journal:  Diabetes Care       Date:  2007-03       Impact factor: 19.112

3.  Accuracy and precision of the Axis-Shield Afinion hemoglobin A1c measurement device.

Authors:  Jamie R Wood; Brett M Kaminski; Craig Kollman; Roy W Beck; Callyn A Hall; Jason P Yun; Eda Cengiz; Michael J Haller; Krishna Hassan; Georgeanna J Klingensmith; William V Tamborlane
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

4.  The effect of elevated fetal hemoglobin on hemoglobin A1c results: five common hemoglobin A1c methods compared with the IFCC reference method.

Authors:  Curt L Rohlfing; Shawn M Connolly; Jack D England; Steven E Hanson; Christina M Moellering; Janielle R Bachelder; Randie R Little
Journal:  Am J Clin Pathol       Date:  2008-05       Impact factor: 2.493

5.  Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria.

Authors:  Erna Lenters-Westra; Robbert J Slingerland
Journal:  Clin Chem       Date:  2009-11-19       Impact factor: 8.327

6.  Point-of-care assays for hemoglobin A(1c): is performance adequate?

Authors:  Randie R Little; Erna Lenters-Westra; Curt L Rohlfing; Robbert Slingerland
Journal:  Clin Chem       Date:  2011-06-28       Impact factor: 8.327

7.  Immediate feedback of HbA1c levels improves glycemic control in type 1 and insulin-treated type 2 diabetic patients.

Authors:  E Cagliero; E V Levina; D M Nathan
Journal:  Diabetes Care       Date:  1999-11       Impact factor: 19.112

8.  Rapid A1c availability improves clinical decision-making in an urban primary care clinic.

Authors:  Christopher D Miller; Catherine S Barnes; Lawrence S Phillips; David C Ziemer; Daniel L Gallina; Curtiss B Cook; Sandra D Maryman; Imad M El-Kebbi
Journal:  Diabetes Care       Date:  2003-04       Impact factor: 19.112

  8 in total
  3 in total

1.  Analysis: Investigating the quality of POCT devices for HbA1c, what are our next steps?

Authors:  Erna Lenters-Westra; Emma English
Journal:  J Diabetes Sci Technol       Date:  2019-05-21

2.  Long-Term Performance of Point-of-Care Hemoglobin A1c Assays.

Authors:  Sujaytha Paknikar; Rohan Sarmah; Losika Sivaganeshan; Adam Welke; Al Rizzo; Kirk Larson; Marc Rendell
Journal:  J Diabetes Sci Technol       Date:  2016-11-01

3.  Assessment of Two Diabetes Point-of-care Analyzers Measuring Hemoglobin A1c in the Peruvian Amazon.

Authors:  Anthony T Saxton; J Jaime Miranda; Ernesto J Ortiz; William Pan
Journal:  Ann Glob Health       Date:  2018-11-05       Impact factor: 2.462

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.